NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors

被引:1
|
作者
Wang, Yahui [1 ,2 ]
Liu, Xinyi [1 ]
Zuo, Xianbo [3 ]
Wang, Cuiling [1 ]
Zhang, Zheng [1 ]
Zhang, Haitao [1 ]
Zeng, Tao [4 ]
Chen, Shunqi [1 ]
Liu, Mengyu [1 ]
Chen, Hongxia [1 ]
Song, Qingfeng [5 ]
Li, Qi [1 ,6 ]
Yang, Chenning [1 ]
Le, Yi [7 ]
Xing, Jinliang [8 ]
Zhang, Hongxin [2 ,9 ]
An, Jiaze [10 ]
Jia, Weihua [11 ,12 ]
Kang, Longli [13 ]
Zhang, Hongxing [6 ]
Xie, Hui [14 ]
Ye, Jiazhou [15 ]
Wu, Tianzhun [15 ]
He, Fuchu [2 ]
Zhang, Xuejun [16 ,17 ]
Li, Yuanfeng [1 ]
Zhou, Gangqiao [1 ,18 ]
机构
[1] Beijing Inst Radiat Med, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[2] Beijing Inst Lifeom, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Dermatol, Dept Pharm, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Fac Hepatobiliary Pancreat Surg, Med Ctr 1, Beijing, Peoples R China
[5] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Guangxi, Peoples R China
[6] Univ South China, Sch Med, Dept Neurosci, Hengyang, Hunan, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary Surg, Med Ctr 5, Beijing, Peoples R China
[8] Air Force Med Univ, Expt Teaching Ctr Basic Med, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China
[9] Air Force Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China
[10] Air Force Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
[11] State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China
[12] Sun Yat Sen Univ, Dept Expt Res, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[13] Xizang Minzu Univ, Sch Med, Key Lab Mol Genet Mech & Intervent Res High Altitu, Key Lab High Altitude Environm & Genes Related Dis, Xianyang, Shaanxi, Peoples R China
[14] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Oncol, Med Ctr 5, Beijing, Peoples R China
[15] Guangxi Med Univ, Guangxi Liver Canc Diag & Treatment Engn & Technol, Dept Hepatobiliary & Pancreat Surg, Canc Hosp, Nanning, Guangxi, Peoples R China
[16] Anhui Med Univ, Affiliated Hosp 1, Dept Dermatol, Hefei, Anhui, Peoples R China
[17] Anhui Med Univ, Affiliated Hosp 1, Inst Dermatol, Hefei, Anhui, Peoples R China
[18] Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源
CELL GENOMICS | 2024年 / 4卷 / 05期
基金
中国国家自然科学基金;
关键词
GENOME-WIDE ASSOCIATION; DNA-REPAIR; SUSCEPTIBILITY LOCUS; READ ALIGNMENT; CANCER; EXPRESSION; NBS1; PATHOGENICITY; POLYMORPHISM; FRAMEWORK;
D O I
10.1016/j.xgen.2024.100550
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To identify novel susceptibility genes for hepatocellular carcinoma (HCC), we performed a rare -variant association study in Chinese populations consisting of 2,750 cases and 4,153 controls. We identified four HCCassociated genes, including NRDE2 , RANBP17 , RTEL1 , and STEAP3 . Using NRDE2 (index rs199890497 [p.N377I], p = 1.19 3 10 - 9 ) as an exemplary candidate, we demonstrated that it promotes homologous recombination (HR) repair and suppresses HCC. Mechanistically, NRDE2 binds to the subunits of casein kinase 2 (CK2) and facilitates the assembly and activity of the CK2 holoenzyme. This NRDE2-mediated enhancement of CK2 activity increases the phosphorylation of MDC1 and then facilitates the HR repair. These functions are eliminated almost completely by the NRDE2-p.N377I variant, which sensitizes the HCC cells to poly(ADP-ribose) polymerase (PARP) inhibitors, especially when combined with chemotherapy. Collectively, our findings highlight the relevance of the rare variants to genetic susceptibility to HCC, which would be helpful for the precise treatment of this malignancy.
引用
收藏
页数:34
相关论文
共 33 条
  • [1] CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
    Lu, Xue
    He, Yaowu
    Johnston, Rebecca L.
    Nanayakarra, Devathri
    Sankarasubramanian, Sivanandhini
    Lopez, J. Alejandro
    Friedlander, Michael
    Kalimutho, Murugan
    Hooper, John D.
    Raninga, Prahlad V.
    Khanna, Kum Kum
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [2] Homologous recombination deficiency and PARP inhibitors in therapeutics
    Salaun, Helene
    Saint-Ghislain, Mathilde
    Bellesoeur, Audrey
    Beuzeboc, Philippe
    Neuzillet, Cindy
    Dieras, Veronique
    Stern, Marc Henri
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2022, 109 (01) : 76 - 82
  • [3] Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
    Xiao, Yinan
    Wu, Yu
    Wang, Qilong
    Li, Mo
    Deng, Chaolin
    Gu, Xiaoyang
    CELL COMMUNICATION AND SIGNALING, 2025, 23 (01)
  • [4] PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
    Keung, Man Yee T.
    Wu, Yanyuan
    Vadgama, Jaydutt V.
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (04)
  • [5] The Emerging Role of Homologous Recombination Repair and PARP Inhibitors in Genitourinary Malignancies
    Rimar, Kalen J.
    Tran, Phuoc T.
    Matulewicz, Richard S.
    Hussain, Maha
    Meeks, Joshua J.
    CANCER, 2017, 123 (11) : 1912 - 1924
  • [6] Knockdown of NRAGE Impairs Homologous Recombination Repair and Sensitizes Hepatoblastoma Cells to Ionizing Radiation
    Liu, Li
    Cui, Zhongqi
    Zhang, Jie
    Wang, Jing
    Gu, Song
    Ma, Ji
    Chen, Hao
    Hang, Liang
    Yang, Jin
    Shi, Yi
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (01) : 41 - 49
  • [7] Loss of CENP-I Impairs Homologous Recombination and Sensitizes Cells to PARP1 Inhibition
    Dang, Tuyen T.
    Morales, Julio C.
    CANCERS, 2021, 13 (13)
  • [8] BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
    Zhang, Shaolu
    Peng, Xin
    Li, Xiaofei
    Liu, Hongyan
    Zhao, Baoquan
    Elkabets, Moshe
    Liu, Yao
    Wang, Wei
    Wang, Ran
    Zhong, Yuxu
    Kong, Dexin
    CELL DEATH & DISEASE, 2021, 12 (06)
  • [9] ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
    Shen, Jianfeng
    Peng, Yang
    Wei, Leizhen
    Zhang, Wei
    Yang, Lin
    Lan, Li
    Kapoor, Prabodh
    Ju, Zhenlin
    Mo, Qianxing
    Shih, Ie-Ming
    Uray, Ivan P.
    Wu, Xiangwei
    Brown, Powel H.
    Shen, Xuetong
    Mills, Gordon B.
    Peng, Guang
    CANCER DISCOVERY, 2015, 5 (07) : 752 - 767
  • [10] Natural product Pulsatilla saponin D sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair
    Lin, Shengbin
    Sun, Binghe
    Zhu, Yin
    Huang, Yi
    Qin, Yu
    Yao, Nan
    Liu, Yongzhu
    Chen, Guo
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2025, : 511 - 523